Mary L. Yost
After a successful career as a Wall Street medical device analyst, Mary L. Yost co-founded THE SAGE GROUP to specialize in what was at the time a little known, but widely prevalent cardiovascular problem, peripheral artery disease (PAD).
Over the past 18 years THE SAGE GROUP has become a leader in PAD research and consulting services. Ms. Yost’s original training as an economist at the University of California Berkeley has led to extensive research on the economic and societal costs of PAD and critical limb ischemia (CLI) as well as on costs and consequences of dysvascular amputation.
Other areas of research focus include disease prevalence, epidemiology of PAD, CLI, calcium, thrombus, ischemic diabetic foot ulcers (DFU) and acute limb ischemia. Knowledge of therapeutic solutions includes medical divices for interventional therapy well as pharmaceutical and stem cell treatments.
Ms. Yost developed the Diabetes Method, a population-based projection model, which is believed to provide the most accurate estimates of the number of people with PAD as well as CLI, intermittent claudication (IC) and asymptomatic disease. To date the Diabetes Method has been employed to estimate PAD in the U.S., Western Europe, China, Japan, India, Mexico and South America.
Ms. Yost has lectured at the following medical meetings: New Cardiovascular Horizons (NCVH) 2010-2020, NCVH, Florida and Minneapolis, AMP-Amputation Prevention Symposium, Outpatient Endovascular and Interventional Society (OEIS) Annual Meeting 2014, Mexican Society of Angiology & Vascular Surgery, First Annual Merck Serono Forum on the Clinical and Economic Burden of Peripheral Arterial Disease in Mexico, New Advances in Cardiovascular and Endovascular Technologies (NACET), Save A Leg Save A Life (SALSAL) National Conference and the Medscape CME Program: The Price of PAD: The Clinical and Economic Consequences of Amputation.